AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: torso position rising 30° at the end
Description: measurement in the recovery unit
Study NCT04492163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTFields
Description: TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.~Other Names:~• TTFields
Study NCT00525733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir 800 mg
Description: darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
Study NCT00525733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir 800 mg
Description: darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
Study NCT00525733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC 200 mg/TDF 300mg
Description: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
Study NCT00525733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC 200 mg/TDF 300mg
Description: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
Study NCT00525733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
Study NCT00525733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)
Study NCT02028390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImageReview's External Wound Trace Overlay
Description: Study staff overlay the trace of the visual external wound's perimeter onto the corresponding thermal image of the external wound.
Study NCT02028390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImageReview's unaffected reference area selected
Description: Study Staff select an unaffected reference area of an adjacent body surface.
Study NCT02028390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjacent tissue trace of the wound trace overlay
Description: Study staff select an adjacent tissue trace of the wound trace overlay
Study NCT00506025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry Juice
Description: Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
Study NCT00506025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: De-Activated Cranberry juice
Description: De-Activated Cranberry juice in the am, then placebo (P) in the pm
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: AR882
Description: Single dose of AR882 or matching placebo
Study NCT00525733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir 100 mg
Description: one tablet of ritonavir is taken with darunavir daily
Study NCT00525733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg
Description: one tablet of ritonavir is taken with darunavir daily
Study NCT03873389 — intervention group
Intervention type: DRUG
Intervention: Ocrelizumab
Description: Patients who are beginning this medication based on patient's treating physician's recommendation will be enrolled in the study.
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 1: AR882
Description: Single dose of AR882 or matching placebo
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: AR882
Description: Single dose of AR882 or matching placebo
Study NCT00929682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomization between two referenced treatments
Description: Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1.
Study NCT00929682 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Randomization between two referenced treatments
Description: Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1.
Study NCT01085097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered per dose and schedule specified in the arm description.
Study NCT01085097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.
Study NCT01085097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.
Study NCT01085097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone/Prednisone
Description: Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.
Study NCT01085097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone/Prednisone
Description: Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.
Study NCT01085097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Study NCT01085097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 2: AR882
Description: Single dose of AR882 or matching placebo
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3: AR882
Description: Single dose of AR882 or matching placebo
Study NCT01085097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone (MP) will be administered per dose and schedule specified in the arm description.
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 3: AR882
Description: Single dose of AR882 or matching placebo
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 4: AR882
Description: Single dose of AR882 or matching placebo
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 4: AR882
Description: Single dose of AR882 or matching placebo
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 5: AR882
Description: Single dose of AR882 or matching placebo
Study NCT03310385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHX02
Description: Herbal medicine originating from gualouhengryunhwan
Study NCT03310385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT03310385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets
Study NCT03485196 — intervention group
Intervention type: OTHER
Intervention: Microsatellite instability
Description: The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.
Study NCT01601262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Extracorporeal Shock waves (Cardiospec 1000)
Description: We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
Study NCT01085097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone (MP) will be administered per dose and schedule specified in the arm description.
Study NCT03357692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: all on four implant rehabilitation
Description: implant insertion after piezoelectric site preparation for trans-sinusal implants
Study NCT02797847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-TTRSC02
Description: Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection
Study NCT02797847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study NCT04735120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLASE DIODE LASERS
Description: 940nm diode laser with 1.5 watts activated in a continuous mode and applied on to the canal orifices during root canal treatment to reduce intraoperative pain and further its effect on post operative pain is assessed
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 5: AR882
Description: Single dose of AR882 or matching placebo
Study NCT00174655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicine + docetaxel sequential
Description: doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
Study NCT00174655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicine + cyclophosphamide sequential
Description: doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
Study NCT00174655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicine + cyclophosphamide combined
Description: doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
Study NCT00174655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicine + docetaxel combined
Description: doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
Study NCT01060033 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MR Spectroscopy
Study NCT01060033 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fat-Saturation and Diffusion-Weighted Imaging
Study NCT01060033 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dynamic Contrast Enhancement MRI (MR-DCE)
Study NCT01060033 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Diffusion Tensor Imaging (DTI)
Study NCT04069156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LVAD Implant
Description: Subjects will undergo Heartmate 3 LVAD implant prior to randomization
Study NCT04069156 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LVAD Implant
Description: Subjects will undergo Heartmate 3 LVAD implant prior to randomization
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 6: AR882 Food Effect
Description: Single dose of AR882 or matching placebo in a fed state
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 6: AR882 Food Effect
Description: Single dose of AR882 or matching placebo in a fed state
Study NCT04069156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Description: Subjects will be randomized to either Placebo or Aspirin post implant.
Study NCT04069156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Subjects will be randomized to either Placebo or Aspirin post implant
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 7: AR882 Solid Oral Formulation
Description: Single dose of AR882 or matching placebo
Study NCT01771432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic treatment
Description: Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
Study NCT01771432 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
Study NCT03676881 — intervention group
Intervention type: DEVICE
Intervention: Computerized cognitive battery: Cognigram (CG)
Description: is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 7: AR882 Solid Oral Formulation
Description: Single dose of AR882 or matching placebo
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 8: AR882 in combination with allopurinol
Description: Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 8: AR882 in combination with allopurinol
Description: Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 9: AR882 in combination with febuxostat
Description: Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
Study NCT03676881 — intervention group
Intervention type: DEVICE
Intervention: The NeuroCatch™ Platform (NCP)
Description: the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.
Study NCT00504595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885 (investigational)
Description: The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Study NCT00504595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Study NCT03207932 — intervention group
Intervention type: PROCEDURE
Intervention: Central vein catheterisation
Description: ultrasound guided versus landmark central vein catheterisation
Study NCT04253288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Morbidity Mortality Review (MMR)
Description: * Standardization of Morbidity Mortality Review (MMR) in radiotherapy centers~* National database from MMR board meetings which include clinical , radiation technique and biological parameters of intrinsic radiosensitivity of patients
Study NCT00764530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alumina/Alumina
Description: CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
Study NCT04347005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 9: AR882 in combination with febuxostat
Description: Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
Study NCT01381549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
Study NCT00764530 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
Study NCT02736045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: emWave
Description: Our approach will be to test the impact of this intervention through a smartphone application, emWave software, which will be provided to all our subjects. emWave is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention (emWave - computer based resilience training program).
Study NCT01678417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-rituximab
Study NCT01376271 — intervention group
Intervention type: DRUG
Intervention: Paroxetine
Study NCT02532296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Coach (TC)
Description: TC reviews patient's medical record to understand current admission and the medical/psycho-social history. TC makes introductory hospital visit(s) with patient to establish rapport and to define post-discharge needs.~Starting in-house and continuing after discharge, TC helps patient set transition goals to maximize healthcare outcomes. Post-discharge, TC offers a voluntary face-to-face visit with patient along with weekly outreach calls, which are designed to assist patient with goal setting and attainment, medical system navigation; medication management; medical follow-up; transportation; use of community resources; and self-care.~Intervention lasts 30 days post-discharge; afterwards TC seeks to handoff to an outpatient care team member, to ensure continuity of care.
Study NCT02532296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Receives usual hospital-based care, discharge preparation, transitional care and outpatient care.
Study NCT03617081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-2023
Description: Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.
Study NCT03617081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0113-2023)
Description: Participants will receive NNC0174-0833 matched placebo orally.
Study NCT02074995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BVS857
Description: Group 1A\&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
Study NCT02074995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
Study NCT03784885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD07010
Description: A protein based adjuvant
Study NCT03784885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza vaccine
Description: Inactivated trivalent seasonal influenza vaccine
Study NCT03784885 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated trivalent influenza vaccine
Description: Inactivated trivalent seasonal influenza vaccine
Study NCT00844363 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: NB-UVB
Description: UVB light will be administered to the entire body except for the genitals in men and eyelids, which will be shielded.NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
Study NCT02154191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Intervention
Description: The clinical intervention in this study is the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
Study NCT01708174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.